【故事】贝达药业股份有限公司董事长丁列明博士：新一轮创新创业的好时代已经到来

2023年8月17日，浙江日报头版头条报道《汇聚磅礴力量 同心勇立潮头——习近平同志在浙江工作期间关于统战工作的探索与实践》，“今日浙江”和“浙江发布”同步刊发。这篇由人民日报和中国新闻社记者历时一年采写而成的重磅报道，连日来在全省社会各界引起了广泛而热烈的反响。贝达药业股份有限公司董事长丁列明博士，作为党外知识分子创新创业的代表，正是报道的典型人物之一，文中详细讲述了习近平总书记在浙江工作期间批示关心贝达新药研发的故事。

“正是总书记当年的批示，照亮了我们的追梦之旅，让我们做成了在美国都做不到的事，实现了创新创业的梦想和价值。” 学习完报道的丁列明备受鼓舞，“这个故事，去年6月编入了中宣部统筹指导、省委宣传部组织编写的《干在实处 勇立潮头——习近平浙江足迹》一书，今年5月30日被《人民日报》头版刊发的《习近平总书记关心科技工作者的故事》报道，这次又得到省级权威媒体的报道，对贝达是莫大的肯定和激励，进一步激发了我们勇攀世界科技高峰的信心与决心。”

总书记批示关心的新药凯美纳（盐酸埃克替尼）已于2011年获批上市，上市12年已惠及50多万晚期非小细胞肺癌病人。这个由丁列明博士带领海归高层次人才团队自主研发的新药，是中国第一个小分子靶向抗癌药，打破了进口药的垄断，被誉为民生领域的“两弹一星”，荣获中国化学制药行业和浙江省企业界第一个也是迄今唯一的国家科技进步一等奖。CXO UNION-CXO联盟（cxounion.cn）

继凯美纳之后，丁列明带领团队又成功研发出中国第一个针对肺癌ALK突变的创新药贝美纳（盐酸恩沙替尼）、第一个用于治疗肾癌的靶向药伏美纳（伏罗尼布）、三代EGFR–TKI赛美纳（甲磺酸贝福替尼）以及浙江省首个贝伐珠单抗生物类似药贝安汀，多次填补国内省内空白，目前在研新药有40多项，其中18项进入临床阶段。

成立20年的贝达，在澎湃激荡的民营经济发展和医药创新浪潮中勇毅前进，作为开拓者、实践者、受益者，已从一家只有几个人的初创企业，成长为近2000名员工的上市公司，成为中国医药创新领域的标杆，正在向“总部在中国的跨国制药企业”迈进。“做好药，让老百姓活得更好，这是贝达的使命，也是我们一直坚持的初心。”丁列明说道。

1963年，丁列明出生于嵊州市石璜镇的一个小山村。1979 年，年仅16岁的他乘着恢复高考的“春风”，考取了浙江医科大学（现浙江大学）。1984年，丁列明大学毕业后，被分配在嵊县卫生防疫站担任实习研究员。没有停下学习深造脚步的他，两年后考取了浙江医科大学硕士研究生，1989年凭借优异的成绩毕业留校任教，1992年作为访问学者被公派赴美留学。在美国的日子里，丁列明勤学刻苦、奋发图强，攻读了阿肯色大学病理学博士学位，并且成为一名受尊敬的病理科执业医师。

在美国学习和工作多年，丁列明亲眼目睹了中美之间在经济、科技等领域的差距，尤其在医药创新方面，差距很大。成长在新中国的他，内心始终怀着报效祖国的念头，从踏上美国的第一天起，回国的想法始终萦绕在他的心间，只是一直在等时机，而新药研发就是这个最好的时机。

2002年夏天，机会终于来了。初创团队几位华裔科学家设计合成了一款靶向抗癌新药，获得了出色的实验室数据。但是在美国，要推进项目成果落地，起码需要花费十亿美金，这并非依靠一个人或者一个小团队就能实现的，团队充其量只能早期开发一段，最后还是要卖给大公司。

当时的中国，新药研制尚处于一块处女地，绝大部分是仿制药，自主研发的新药寥寥无几，可与国际竞争的尖端新药更是罕见。但，中国正在成为全球瞩目的创新创业热土，经济高速发展，资本日益雄厚，中国有能力有意愿进行高科技项目的投资，市场亦很大。站在十字路口，往哪里走？答案不言自明。丁列明说：“当时，大家经过讨论，一致认为要把这个项目系统做起来，还是要回到中国来。很快，我们做出决定：回国创业！把成果献给祖国和人民，争取让中国患者吃上中国人自己做的药！”2002年8月13日，在美国阿肯色州小石城机场，丁列明登上泛美航空公司的班机，告别拼搏奋斗了10年的美国，毅然回国开始了自己的创业新征程。2003年1月7日，贝达药业在杭州体育场路三间租来的办公室里成立，同时在北京一所大学租了间实验室，成立北京新药研究开发中心，开始新药研发。这一年，正逢习近平总书记亲自谋划制定的“八八战略”启航。创新难，做创新药更是难上加难。国际医药界有个通行的“双十”说法，即研制一款新药平均要耗时10年之久，投入10亿美金。从技术、资金，到审批、临床试验，再到上市销售，每一个关键节点都是一次大考。丁列明回忆，当时的国内新药研发环境尚不成熟，要实现从“0”到“1”，每一步都走得异常艰难，需克服无数的技术难关，经历一次次失败，还有资金关、审批关和产业化关等等。创新难，做创新药更是难上加难。国际医药界有个通行的“双十”说法，即研制一款新药平均要耗时10年之久，投入10亿美金。从技术、资金，到审批、临床试验，再到上市销售，每一个关键节点都是一次大考。丁列明回忆，当时的国内新药研发环境尚不成熟，要实现从“0”到“1”，每一步都走得异常艰难，需克服无数的技术难关，经历一次次失败，还有资金关、审批关和产业化关等等。CXO UNION-CXO联盟（cxounion.cn）

危急关头，区委、区政府雪中送炭伸出援手，通过下属创投引导基金提供了1500万元的资金支持，一下子解决了燃眉之急。2008年启动的国家重大新药创制专项基金也提供了有力支持，浙江省、杭州市也以不同的方式予以扶持，众人拾柴火焰高，贝达弥补了资金缺口。绝处逢生！2009年2月，凯美纳III期临床试验得以启动。

III期临床试验由中国肿瘤内科泰斗、中国医学科学院肿瘤医院孙燕院士领衔把关。为了确保成功，丁列明发挥专业特长，决定打破当时常规的临床试验设计，第一次选择以国际品牌专利药为阳性对照，进行头对头的随机双盲试验。这是一个风险极大的试验方案，一旦数据不如对照药，将会前功尽弃，但基于对自己产品的足够信心，团队决定要冒这个险。试验结果十分喜人，凯美纳在疗效和安全性方面均超过了进口药。数据一公布，不少投资公司和跨国药企纷纷找上了门，其中有一家跨国企业报出了2.5亿美元的高价要收购这个项目。尽管当时贝达背负的银行欠款已经达到了1.5亿元，但丁列明依然毫不犹豫地拒绝了对方的收购意向，因为他始终牢记“做好药，让老百姓活得更好”的初心。凯美纳上市时，尽管疗效和安全性都优于进口药，但丁列明依旧坚持定价比进口药低30%-40%，这一切都是为了让更多病人吃得起中国人自主研发的好药。让病人看到生的希望，不再“谈癌变色”，就是要做老百姓吃得到、吃得起的好药。2011年，凯美纳正式上市后，为更好地帮助病人解决长期用药的经济困难，贝达在大幅降价的基础上，再开展后续免费用药项目，只要病人连续6个月服用凯美纳确实有效，凭借医生所出具的相关证明，便可获得终身后续免费用药。赠药政策并不少见，但是像这样终身免费的却几乎没有。如今凯美纳免费赠药已达810多万盒，市场价值已经超过130亿元，确实可以说是一款“老百姓吃得起的好药”。CXO UNION-CXO联盟（cxounion.cn）

除了免费赠药以外，贝达在抗癌药进入医保的过程中也扛起了民族药企的担当。2016年底，国家医保目录谈判全面开启，凯美纳作为首个国产新药参加谈判。众所周知，药品想要进入医保目录，首先就要将销售价格大幅自降，有时甚至超过一半，这对于许多外企来说是不能接受的。因此国谈开始后，在倍受病人关注的抗癌药方面，迟迟得不到突破性进展。当谈判陷入僵局时，贝达主动站了出来，率先承诺降价54%，这毅然决然的降价，让此前依靠高价占领中国市场的外企措手不及，只能妥协，同样大幅降价进入到医保，让中国患者受益。当时的国家医保部门领导充满感慨地说道，没有贝达自主研发的创新药，想让外企降价，放以前是想都不敢想的事。

2017年，贝达再次响应国家号召，推动凯美纳在降价54%参加国家药品价格谈判的基础上，又降价3.86%。2021年凯美纳术后辅助治疗适应症获批，再次大幅度降价被纳入新版国家医保目录，更好地惠及患者。同样被纳入国家医保目录和实行免费用药政策的，还有贝美纳。现如今，适用的晚期肺癌病人基本都用上了靶向药，治疗费用早已不再像以前一样动辄几十万，大幅降低的药费大大减轻了病人的经济负担，真正让需要的病人用上了救命药，使《我不是药神》电影中描述的癌症病人用不上救命药的悲剧成为了历史。凭借突出的创新价值和经济社会效益，凯美纳荣获2015年度国家科技进步一等奖，丁列明在北京人民大会堂接受奖励，并得到了习近平总书记的亲切接见。凯美纳和贝美纳还双双入选国家“十三五”科技创新成就展。

创新是立身之本，是贝达与生俱来的基因。丁列明始终相信，只有坚定不移走创新驱动发展道路，通过强化科技自立自强，才能实现企业的高质量发展，“正如习近平总书记所强调的，关键核心技术的确是要不来、买不来、讨不来的，只能靠自己。” CXO UNION-CXO联盟（cxounion.cn）

为此贝达广聚优秀人才，构建国内领先的肿瘤靶向创新药物研发和产业化体系，在杭州、北京拥有两大新药研发中心，在临平、嵊州建设新药产业化基地，并不断增加新药研发投入，近几年每年都把营业收入的40%投入到研发中。目前，除了已经上市的5款产品，在研新药项目已达40多项，涵盖靶向新药和免疫疗法，兼有小分子和大分子多种抗癌新药机制，其中有18项进入临床研究阶段，未来发展充满潜力。

在自主创新的同时，丁列明充分发挥贝达作为领军企业的龙头作用，主导打造了生物医药产业孵化平台贝达梦工场，配置空间和资金，帮助更多科学家创新创业。现在，贝达梦工场已孵化几十家医药企业，突出代表是与北京大学邓宏魁教授合作创立的瑞普科技，开展干细胞治疗糖尿病转化研究。2018年5月，习近平总书记在北京大学视察时曾听取邓教授的汇报，并关心何时能进入临床研究。如今，该项目已经进入临床研究，第一例病人显示良好的疗效和安全性，在国际上处于领先水平。

与此同时，丁列明主导设立的贝达生物医药产业基金也已投资几十家医药创新企业，三家已成功上市。特别值得一提的是投资的武汉禾元生物科技股份有限公司，其自主研发的植物源重组人血清白蛋白注射液，是目前全球唯一一个应用植物表达体系将重组人血清白蛋白，临床意义十分巨大，可解除对进口产品的依赖，也已获批进入临床研究，前景可期。CXO UNION-CXO联盟（cxounion.cn）

谈及未来发展，丁列明信心满满。“在‘八八战略’指引下，20年创新创业历程中，我们见证了浙江大地翻天覆地的变化，充分感受到了浙江无比优越的创新创业环境和民营经济发展的独特优势。”丁列明表示，近期，党中央、国务院出台《关于促进民营经济发展壮大的意见》，省委、省政府召开民营企业家座谈会，研究制订浙江促进民营经济高质量发展的举措，让大家切实感到新一轮创新创业的好时代已经到来，扎根浙江这块民营经济发展沃土，贝达一定会迎来新的发展机遇。

“随着杭州亚运会开幕在即，大家将更加深刻地感受到健康的重要性。”丁列明说，20年风华正茂，站在新起点上的贝达，将牢记总书记批示精神，聚焦老百姓健康需求，充分发挥民营企业在科技创新中的主体作用，努力研发出更多老百姓吃得起的好药，为推动浙江生物医药产业和民营经济高质量发展，为建设生命健康科创高地、打造“重要窗口”不断作出新贡献。

翻译：

This heavy report by the People’s Daily and China News Service reporters, which took a year to collect and write, has aroused a wide and warm response in all sectors of the province in recent days.

“It was the General secretary’s instructions that illuminated our journey to pursue our dreams, allowing us to accomplish what we could not do in the United States. And realize the dream and value of innovation and entrepreneurship.” This time, it has been reported by the provincial authoritative media, which is a great affirmation and incentive for Beida. And further inspires our confidence and determination to climb the world’s scientific and technological peak.”CXO UNION-CXO联盟（cxounion.cn）

The new drug Kemena (Ectinib hydrochloride), which was approved by the General Secretary, was listed in 2011 and has benefited more than 500,000 patients with advanced non-small cell lung cancer in the past 12 years. This new drug, independently developed by Dr. Ding Liming led by the overseas high-level talent team. Is China’s first small molecule targeted anti-cancer drug, breaking the monopoly of imported drugs, known as the “two bombs and one star” in the field of people’s livelihood, and won the first and so far the only National science and Technology Progress Prize in China’s chemical pharmaceutical industry and Zhejiang business community.

Following Kemena, he led the team to successfully develop China’s first innovative drug Bemena (Enshatinib hydrochloride) for lung cancer ALK mutation, the first targeted drug Vomena (Vonib) for the treatment of kidney cancer, the third-generation EGFR-TKI Semena (Befortinib mesylate) and the first Bevacizumab biosimilar in Zhejiang Province, Beantin.CXO UNION-CXO联盟（cxounion.cn）

At present, there are more than 40 new drugs in the research and development, of which 18 have entered the clinical stage.

Beida, established 20 years ago, has advanced bravely in the surging wave of private economic development and pharmaceutical innovation, as a pioneer, practitioner and beneficiary, has grown from a start-up with only a few people to a listed company with nearly 2,000 employees, becoming the benchmark in the field of Chinese pharmaceutical innovation, and is moving toward “multinational pharmaceutical enterprises headquartered in China”. “Make good medicine, let the people live better, this is the mission of Beida, and we have always adhered to the original heart.” Ding Liming said.

Ding Lieming was born in a small mountain village in Shihuang Town, Shengzhou City in 1963. In 1979, at the age of 16, he took advantage of the “spring breeze” of the resumption of the National college entrance examination and was admitted to Zhejiang Medical University (now Zhejiang University). In 1984, after graduating from university. Ding Liming was assigned to Shengxian health and epidemic prevention station as an intern researcher.

He did not stop the pace of further study, two years later admitted to Zhejiang Medical University master’s degree, in 1989 with excellent results graduated to teach in the school, in 1992 as a visiting scholar was sent to the United States to study. During his time in the United States, Ding Leeming studied hard and worked hard, earning a doctorate in pathology from the University of Arkansas and becoming a respected licensed pathologist.

Having studied and worked in the United States for many years,

Ding has witnessed the gap between China and the United States in the fields of economy. Science and technology, especially in the field of pharmaceutical innovation. Growing up in New China, he has always had the idea of serving the motherland in his heart. From the first day he set foot on the United States. The idea of returning home has always haunted his heart, but has been waiting for the opportunity. And the research and development of new drugs is the best opportunity.CXO UNION-CXO联盟（cxounion.cn）

In the summer of 2002, the opportunity finally came.

The start-up team of several Chinese scientists designed and synthesized a targeted anti-cancer drug and obtained excellent laboratory data. However, in the United States, it takes at least one billion dollars to push forward the implementation of project results, which can not be achieved by a single person or a small team, the team can only develop a period of early development, and finally sell to a large company.

At that time, the development of new drugs in China was still in a virgin territory. Most of them were generic drugs. There were few new drugs independently developed. And cutting-edge new drugs that could compete with international competition were rare. However, China is becoming a hot land for innovation and entrepreneurship, with rapid economic development and increasingly abundant capital, China has the ability and willingness to invest in high-tech projects, and the market is also large. Standing at the crossroads, where to go?

The answer is self-evident. Ding Lieming said: “At that time, after discussion, we agreed that if we want to make this project system. We should return to China. Soon, we made a decision: come back to start a business! Dedicate the results to the motherland and the people, and strive to let Chinese patients eat the medicine made by Chinese people!” On August 13, 2002, Ding Liming boarded the Pan American Airlines flight at the airport in Little Rock, Arkansas, saying goodbye to the United States after 10 years of hard work and resolutely returning home to start his new journey of entrepreneurship.

On January 7, 2003, Beida Pharmaceutical was established in three rented offices on the Stadium Road in Hangzhou.

And rented a laboratory in a university in Beijing to establish the Beijing New Drug Research and Development Center. Which began the research and development of new drugs. Innovation is difficult, and making innovative drugs is even more difficult. There is a popular “double Ten” saying in the international medical industry, that is. It takes an average of 10 years to develop a new drug and an investment of 1 billion dollars.

From technology, capital, to approval, clinical trials, and then to the market, every key node is a big test. Ding Lieming recalled that the domestic new drug research and development environment at that time was not mature, to achieve from “0” to “1”, each step was extremely difficult, to overcome countless technical difficulties, experienced repeated failures, and capital, approval and industrialization. Innovation is difficult, and making innovative drugs is even more difficult. There is a popular “double Ten” saying in the international medical industry, that is. It takes an average of 10 years to develop a new drug and an investment of 1 billion dollars.CXO UNION-CXO联盟（cxounion.cn）

From technology, capital, to approval, clinical trials.

And then to the market, every key node is a big test. Ding Lieming recalled that the domestic new drug research and development environment at that time was not mature, to achieve from “0” to “1”, each step was extremely difficult, to overcome countless technical difficulties, experienced repeated failures, and capital, approval and industrialization.

At the critical moment, the district Party committee and the district government offered a helping hand in the middle of the crisis, and provided 15 million yuan of financial support through the subordinate venture capital guidance fund, which suddenly solved the urgent need. The national major new drug creation special fund launched in 2008 also provided strong support. And Zhejiang Province and Hangzhou City also supported in different ways, and Beda made up for the funding gap. Come back from the dead! In February 2009, the Phase III clinical trial of Kemena was initiated.

The Phase III clinical trial was supervised by Sun Yan, a leading oncologist in China . And Cancer Hospital of the Chinese Academy of Medical Sciences. In order to ensure success, Ding Lieming gave full play to his professional expertise and decided to break the conventional clinical trial design at that time, and for the first time chose international brand patented drugs as positive controls to conduct a head-to-head randomized double-blind trial. It was an extremely risky trial plan that would have been wasted . If the data was worse than the control drug. But the team decided to take the risk because they had enough confidence in their product. CXO UNION-CXO联盟（cxounion.cn）

The results of the trial were very encouraging, and Kemena outperformed imported drugs in terms of efficacy and safety.

As soon as the data was released, many investment companies and multinational pharmaceutical companies came to the door, including a multinational company that offered a high price of $250 million to buy the project. Although the bank arrears Beida was carrying at that time had reached 150 million yuan, Ding Lieming still refused the other party’s acquisition intention without hesitation, because he always kept in mind the original intention of “doing a good job of medicine, so that the people live better”.

When Kaimena was listed, although the efficacy and safety were better than imported drugs, Dante listed still insisted on pricing 30% to 40% lower than imported drugs, all in order to make more patients affordable to eat the good drugs independently developed by Chinese people. Let the patient see the hope of life, no longer “talk about cancer change color”. Is to be a good medicine that the people can eat and afford. In 2011, after the official listing of Kaimena . In order to better help patients solve the economic difficulties of long-term drug use.

Beda on the basis of substantial price reduction.

And then carry out follow-up free drug projects, as long as patients take Kaimena for 6 months is really effective. With the relevant certificate issued by the doctor, you can get lifelong follow-up free drug. Drug giveaways are not uncommon, but few are free for life. Nowadays, Kaimena free medicine has reached more than 8.1 million boxes. And the market value has exceeded 13 billion yuan. Which can indeed be said to be a “good medicine that people can afford”.CXO UNION-CXO联盟（cxounion.cn）

In addition to the free donation of drugs. Beida also took up the role of national pharmaceutical enterprises in the process of entering the medical insurance of anti-cancer drugs. At the end of 2016, the negotiation of the national medical insurance catalogue was fully opened. And Kemena participated in the negotiation as the first domestic new drug. As we all know, if a drug wants to enter the medical insurance catalogue, it must first reduce its sales price significantly, sometimes even more than half, which is unacceptable for many foreign companies. Therefore, after the start of the national talks. There has been no breakthrough in the anti-cancer drugs that have attracted much attention from patients.

When the negotiations reached an impasse.

Beida took the initiative to stand out and took the lead in promising a price reduction of 54%, which resolutely cut prices, so that foreign companies that previously relied on high prices to occupy the Chinese market were caught off guard, and could only compromise, and also significantly cut prices to enter the medical insurance, so that Chinese patients could benefit. At that time, the leader of the national medical insurance department said with emotion that there was no innovative drug independently developed by Beda, and it was unthinkable to want foreign companies to lower their prices before.

In 2017, Bayda once again responded to the national call. Pushing Kemena to reduce prices by 3.86% on the basis of a 54% reduction in the national drug price negotiation. In 2021, Kemena postoperative adjuvant therapy indications were approved. And once again significantly reduced prices were included. In the new version of the national medical insurance catalog to better benefit patients.

Also included in the national medical insurance directory and the implementation of free drug policy, there is Bemena. Nowadays, the applicable advanced lung cancer patients are basically using targeted drugs. And the treatment cost is no longer hundreds of thousands as before. And the significantly reduced drug cost greatly reduces the economic burden of patients. Truly allowing patients in need to use life-saving drugs. Making the tragedy of cancer patients who cannot use life-saving drugs described in the movie “I am Not a Medicine God” become history. Kemena and Bemena were also selected for the national “13th Five-Year” scientific and Technological Innovation Achievement Exhibition.CXO UNION-CXO联盟（cxounion.cn）

Innovation is the foundation of life, is Beda’s innate genes.

To this end, Beida gathers outstanding talents, builds a leading domestic tumor targeted innovative drug research and development and industrialization system, has two new drug research and development centers in Hangzhou and Beijing, builds a new drug industrialization base in Linping and Shengzhou, and continuously increases the investment in new drug research and development, in recent years, 40% of the operating income is invested in research and development.

At present, in addition to the 5 products that have been listed, there are more than 40 new drug research projects, covering targeted new drugs and immunotherapies, and a variety of anti-cancer new drug mechanisms of small and large molecules, 18 of which have entered the clinical research stage, and the future development is full of potential.

At the same time of independent innovation

Ding Liming gave full play to Beda’s leading role as a leading enterprise. Led the creation of the biomedical industry incubation platform Beda Dream Workshop. llocated space and funds to help more scientists innovate and start businesses.

Now, Beda Dream Factory has incubated dozens of pharmaceutical companies, the most prominent representative is Ruepu Technology, founded in cooperation with Professor Deng Hongkui of Peking University, to carry out transformational research on stem cell treatment of diabetes. Now, the project has entered clinical research, the first patient has shown good efficacy and safety, in the international leading level.

At the same time, the Beida Biomedicine Industry Fund led by Ding Liming has also invested in dozens of pharmaceutical innovation companies. And three have been successfully listed. Especially worth mentioning is the investment of Wuhan Heyuan Biotechnology its independent research and development of plant source recombinant human serum albumin injection. Is currently the world’s only application of plant expression system will recombinant human serum albumin, clinical significance is very great, can remove the dependence on imported products, has also been approved to enter clinical research, the prospect can be expected.CXO UNION-CXO联盟（cxounion.cn）

When it comes to future development, Ding Lieming is full of confidence.

“Under the guidance of the ’88 Strategy’, in the course of 20 years of innovation and entrepreneurship, we have witnessed earth-shaking changes in Zhejiang, and fully felt the unique advantages of Zhejiang’s unparalleled innovation and entrepreneurship environment and private economic development.” Ding Liming said that recently, the Party Central Committee and The State Council issued the Opinions on Promoting the Development. And Growth of the Private Economy.

And the provincial Party Committee and the provincial government convened a forum for private entrepreneurs to study and formulate measures to promote the high-quality development of the private economy in Zhejiang, so that everyone can truly feel that a good era of a new round of innovation and entrepreneurship has arrived, and take root in the fertile soil for the development of the private economy in Zhejiang. Beida will surely embrace new development opportunities.CXO UNION-CXO联盟（cxounion.cn）

“With the opening of the Asian Games in Hangzhou, people will feel the importance of health more deeply.

” Ding Liming said that 20 years in the prime of youth, standing at a new starting point, Beda will bear in mind the spirit of the General Secretary’s instructions, focus on the health needs of the people, give full play to the main role of private enterprises in scientific and technological innovation.

And strive to develop more good medicines that the people can afford to eat. In order to promote the high-quality development of Zhejiang’s biomedical industry and private economy. Continue to make new contributions to the construction of life and health science and innovation highland . And create an “important window”.

本文由CXO UNION-CXO联盟（cxounion.cn）转载而成，来源于浙商之家；编辑/翻译：CXO UNIONCXO联盟小U。

如需加入CXO UNION（CXO联盟）高管社群，请联系社群小伙伴哦~

免责声明: 本网站(http://www.cxounion.cn/)内容主要来自原创、合作媒体供稿和第三方投稿，凡在本网站出现的信息，均仅供参考。本网站将尽力确保所提供信息的准确性及可靠性，但不保证有关资料的准确性及可靠性，读者在使用前请进一步核实，并对任何自主决定的行为负责。本网站对有关资料所引致的错误、不确或遗漏，概不负任何法律责任。

本网站刊载的所有内容(包括但不仅限文字、图片、LOGO、音频、视频、软件、程序等) 版权归原作者所有。任何单位或个人认为本网站中的内容可能涉嫌侵犯其知识产权或存在不实内容时，请及时通知本站，予以删除。